

# Lorenza Rimassa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2374079/publications.pdf>

Version: 2024-02-01

262  
papers

13,673  
citations

38660

50  
h-index

28224

105  
g-index

267  
all docs

267  
docs citations

267  
times ranked

13605  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63.	13.9	1,677
2	Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 486-492.	0.8	835
3	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
4	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 55-63.	5.1	522
5	Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 766-776.	13.9	448
6	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. <i>Lancet Oncology</i> , The, 2011, 12, 1101-1108.	5.1	356
7	Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. <i>Journal of Clinical Oncology</i> , 2008, 26, 5569-5575.	0.8	299
8	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
9	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693.	5.1	285
10	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 165-171.	2.9	279
11	Molecular therapies for HCC: Looking outside the box. <i>Journal of Hepatology</i> , 2020, 72, 342-352.	1.8	250
12	Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 995-1008.	5.1	237
13	Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. <i>Journal of Clinical Oncology</i> , 2022, 40, 379-379.	0.8	235
14	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021, 75, 960-974.	1.8	217
15	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 57, 101-107.	1.8	191
16	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 413-423.	3.7	180
17	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. <i>British Journal of Cancer</i> , 2008, 99, 83-89.	2.9	167
18	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. <i>Annals of Oncology</i> , 2009, 20, 1489-1498.	0.6	163

#	ARTICLE	IF	CITATIONS
19	Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2019, 77, 20-28.	3.4	159
20	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 3620-3637.	2.6	154
21	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	7.7	151
22	Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 543-553.	1.2	145
23	5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. <i>Journal of Clinical Oncology</i> , 1998, 83, 372-378.		139
24	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	1.8	132
25	Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. <i>Annals of Oncology</i> , 2013, 24, 406-411.	0.6	126
26	Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 739-745.	1.1	116
27	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	3.6	114
28	Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. <i>Gut</i> , 2012, 61, 268-277.	6.1	101
29	Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. <i>Liver Cancer</i> , 2017, 6, 16-26.	4.2	97
30	Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epirubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 601-607.	3.0	96
31	A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. <i>Annals of Oncology</i> , 2015, 26, 542-547.	0.6	96
32	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	1.1	96
33	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020, 123, 403-409.	2.9	93
34	SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. <i>Radiation Oncology</i> , 2013, 8, 148.	1.2	91
35	Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. <i>Oncotarget</i> , 2017, 6, e1342918.	2.1	90
36	Systemic Treatment Options in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 427-446.	4.2	89

#	ARTICLE	IF	CITATIONS
37	Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. <i>BMC Cancer</i> , 2014, 14, 619.	1.1	86
38	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , 2014, 25, 1373-1378.	0.6	84
39	Tumor-Derived Prostaglandin E2 Promotes p50 NF- $\kappa$ B-Dependent Differentiation of Monocytic MDSCs. <i>Cancer Research</i> , 2020, 80, 2874-2888.	0.4	81
40	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Clinical and Experimental Immunology</i> , 2016, 185, 61-71.	1.1	75
41	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
42	Systemic treatment of HCC in special populations. <i>Journal of Hepatology</i> , 2021, 74, 931-943.	1.8	72
43	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	3.4	70
44	A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. <i>British Journal of Cancer</i> , 2013, 108, 21-24.	2.9	69
45	MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 1077-1086.	1.9	68
46	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 3099-3110.	0.8	65
47	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 207-207.	0.8	62
48	Gastric cancer: Translating novel concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019, 79, 101889.	3.4	60
49	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. <i>Oncotarget</i> , 2016, 7, 72622-72633.	0.8	60
50	FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1478-1485.	0.8	59
51	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 397-409.	1.8	59
52	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 1938-1951.	0.4	58
53	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 4795-4804.	3.2	58
54	ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100347.	2.6	57

#	ARTICLE	IF	CITATIONS
55	<p></p>Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date</p>. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 31-39.	1.8	55
56	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. European Journal of Cancer, 2019, 118, 121-130.	1.3	51
57	Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncology, 2020, 16, 1525-1536.	1.1	50
58	Time-Dependent COVID-19 Mortality in Patients With Cancer. JAMA Oncology, 2022, 8, 114.	3.4	50
59	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncology, The, 2022, 23, 865-875.	5.1	50
60	Characterisation of the immune-related transcriptome in resected biliary tract cancers. European Journal of Cancer, 2017, 86, 158-165.	1.3	47
61	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers, 2020, 12, 1862.	1.7	47
62	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
63	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver International, 2021, 41, 1389-1397.	1.9	45
64	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers, 2022, 14, 186.	1.7	44
65	A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Annals of Oncology, 2008, 19, 1888-1893.	0.6	43
66	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 2017, 28, 555-561.	0.6	43
67	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. European Journal of Cancer, 2021, 157, 140-152.	1.3	42
68	Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. European Journal of Cancer, 2010, 46, 2746-2752.	1.3	41
69	High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. Laboratory Investigation, 2018, 98, 95-105.	1.7	41
70	Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. Liver Cancer, 2021, 10, 240-248.	4.2	39
71	Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clinical Trials, 2009, 6, 272-287.	0.7	37
72	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. European Journal of Cancer, 2021, 150, 190-202.	1.3	37

#	ARTICLE	IF	CITATIONS
73	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	2.6	36
74	Caregiver training for a therapeutic alliance in palliative home care.. Journal of Clinical Oncology, 2018, 36, 15-15.	0.8	36
75	Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?. Annals of Surgical Oncology, 2018, 25, 1676-1685.	0.7	35
76	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. Clinical Colorectal Cancer, 2019, 18, 125-132.e2.	1.0	35
77	Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1179-1187.	1.2	34
78	A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Oncologist, 2013, 18, 379-380.	1.9	34
79	Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs in Context, 2018, 7, 1-10.	1.0	34
80	Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1399-1407.	3.3	33
81	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. Targeted Oncology, 2018, 13, 227-234.	1.7	33
82	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. Journal of Autoimmunity, 2019, 100, 17-26.	3.0	33
83	Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Liver International, 2020, 40, 1800-1811.	1.9	33
84	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 583-592.	4.2	33
85	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer, 2017, 20, 825-833.	2.7	32
86	Hepatotoxicity of immune check point inhibitors: Approach and management. Digestive and Liver Disease, 2019, 51, 1074-1078.	0.4	32
87	Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer. JAMA Oncology, 2020, 6, 547.	3.4	32
88	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer, 2019, 8, 281-294.	4.2	31
89	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 370-379.	4.2	31
90	Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.. Journal of Clinical Oncology, 2017, 35, 4000-4000.	0.8	31

#	ARTICLE	IF	CITATIONS
91	Metastasis of Hepatocellular Carcinoma to the Heart: A Case Report and Review of the Literature. <i>Tumori</i> , 2004, 90, 345-347.	0.6	30
92	Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. <i>Hepatology</i> , 2020, 72, 982-996.	3.6	30
93	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
94	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 14408-14415.	0.8	30
95	KRAS mutation in lung metastases from colorectal cancer: prognostic implications. <i>Cancer Medicine</i> , 2016, 5, 256-264.	1.3	29
96	Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. <i>Cancer Immunology Research</i> , 2019, 7, 751-758.	1.6	29
97	Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2010, 103, 837-844.	2.9	28
98	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 315-321.	0.3	28
99	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. <i>Cancers</i> , 2020, 12, 3370.	1.7	28
100	Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2001, 12, S119-S123.	0.6	27
101	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017, 22, 1463-1469.	1.9	27
102	Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases. <i>World Journal of Surgery</i> , 2018, 42, 2651-2659.	0.8	27
103	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0232371.	1.1	27
104	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. <i>Targeted Oncology</i> , 2014, 9, 155-162.	1.7	26
105	Regorafenib for the treatment of unresectable hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 567-576.	1.1	26
106	Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4006-4006.	0.8	26
107	Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. <i>Annals of Oncology</i> , 2002, 13, 1424-1429.	0.6	25
108	Rectal squamous cell carcinoma treated with chemoradiotherapy: report of six cases. <i>International Journal of Colorectal Disease</i> , 2010, 25, 1435-1439.	1.0	25

#	ARTICLE	IF	CITATIONS
109	Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib. <i>World Journal of Gastroenterology</i> , 2011, 17, 2450.	1.4	25
110	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 121, 593-599.	2.9	24
111	ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4017-4017.	0.8	24
112	Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4090-4090.	0.8	24
113	Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4157-TPS4157.	0.8	24
114	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3505-3505.	0.8	23
115	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024.	3.2	22
116	The present and the future landscape of treatment of advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2010, 42, S273-S280.	0.4	21
117	Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. <i>Liver Cancer</i> , 2017, 6, 313-324.	4.2	21
118	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
119	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 38-47.	4.2	20
120	Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110311.	1.4	19
121	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	1.3	19
122	Oral ulcer as an exclusive sign of gastric cancer: report of a rare case. <i>BMC Cancer</i> , 2005, 5, 117.	1.1	18
123	Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection. <i>Journal of Clinical Oncology</i> , 2011, 29, e680-e681.	0.8	17
124	Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. <i>Future Oncology</i> , 2013, 9, 153-165.	1.1	17
125	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 887-897.	1.8	17
126	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. <i>Hepatic Oncology</i> , 2014, 1, 181-188.	4.2	16



#	ARTICLE	IF	CITATIONS
127	Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e489-e498.	1.0	16
128	Hepatocellular Carcinoma: A Global Disease in Need of Individualized Treatment Strategies. <i>Journal of Oncology Practice</i> , 2017, 13, 368-369.	2.5	15
129	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	1.9	15
130	Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. <i>British Journal of Cancer</i> , 2021, 124, 407-413.	2.9	15
131	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110109.	1.4	15
132	Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial. <i>Cancers</i> , 2020, 12, 2790.	1.7	15
133	Unexpected Low Efficacy of Stealth Liposomal Doxorubicin (Caelyx) and Vinorelbine in Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 77, 185-188.	1.1	14
134	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	3.0	14
135	The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study. <i>Investigational New Drugs</i> , 2007, 25, 479-485.	1.2	13
136	Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival. <i>Updates in Surgery</i> , 2010, 62, 63-67.	0.9	13
137	The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. <i>Current Opinion in Oncology</i> , 2021, 33, 386-394.	1.1	13
138	Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. <i>European Journal of Cancer</i> , 2013, 49, 989-998.	1.3	12
139	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET's Letter. <i>Clinical Cancer Research</i> , 2013, 19, 4290-4290.	3.2	12
140	Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. <i>European Journal of Cancer</i> , 2017, 81, 174-182.	1.3	12
141	Cabozantinib for the treatment of hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 847-855.	1.1	12
142	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019, 19, 283.	1.1	12
143	Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2289-2297.	1.2	12
144	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	1.3	12

#	ARTICLE	IF	CITATIONS
145	Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3665-3671.	1.2	12
146	Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms. <i>Pancreatology</i> , 2021, 21, 950-956.	0.5	12
147	Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. <i>Tumori</i> , 2011, 97, 620-8.	0.6	12
148	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 295-306.	1.1	11
149	The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 97-103.	0.4	11
150	FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: AÂPhase II Study. <i>Clinical Colorectal Cancer</i> , 2015, 14, 162-169.	1.0	11
151	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018, 95, 344-352.	0.9	11
152	Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib. <i>Future Oncology</i> , 2019, 15, 2449-2462.	1.1	11
153	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. <i>British Journal of Radiology</i> , 2020, 93, 20190627.	1.0	11
154	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020, 135, 230-239.	1.3	11
155	Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial. <i>Annals of Oncology</i> , 2021, 32, 66-76.	0.6	11
156	Rectal Cancer in Adolescent and Young Adult Patients: Pattern of Clinical Presentation and Case-Matched Comparison of Outcomes. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1064-1073.	0.7	11
157	Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. <i>Cancers</i> , 2021, 13, 4506.	1.7	11
158	Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 908-910.	3.2	11
159	Outcome of liver cancer patients with SARSâ€CoVâ€2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	1.9	11
160	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017, 13, 2265-2275.	1.1	10
161	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4019-4019.	0.8	10
162	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2659-TPS2659.	0.8	10

#	ARTICLE	IF	CITATIONS
163	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2448.	1.4	10
164	Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. <i>BMC Cancer</i> , 2022, 22, 377.	1.1	10
165	Chemotherapy with Mitomycin C and Capecitabine in Patients with Advanced Colorectal Cancer Pretreated with Irinotecan and Oxaliplatin. <i>Tumori</i> , 2006, 92, 285-289.	0.6	9
166	Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer. <i>Chemotherapy</i> , 2010, 56, 203-207.	0.8	9
167	Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?. <i>Cancer Biology and Therapy</i> , 2018, 19, 659-663.	1.5	9
168	The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 177-191.	1.8	9
169	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 927-939.	1.1	9
170	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 401-413.	1.9	9
171	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). <i>Future Oncology</i> , 2019, 15, 4009-4017.	1.1	8
172	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	1.3	8
173	Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4585-4585.	0.8	8
174	Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. <i>Oncologist</i> , 2020, 25, e928-e935.	1.9	8
175	Targeted agents for second-line treatment of advanced hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 788-803.	0.8	8
176	Preliminary Experience with High-Dose Cisplatin, Reduced Glutathione and Natural Interferon- $\gamma$ in Dacarbazine-Resistant Malignant Melanoma. <i>Tumori</i> , 1998, 84, 48-51.	0.6	7
177	Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 423-423.	0.8	7
178	Abstract A089: Exploiting clonal evolution and liquid biopsy to overcome resistance to anti-EGFR treatment in metastatic colorectal cancer: the CHRONOS trial. , 2018, , .		7
179	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	2.0	7
180	Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. <i>European Journal of Cancer</i> , 1995, 31, 2426-2427.	1.3	6

#	ARTICLE	IF	CITATIONS
181	Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers. <i>Tumori</i> , 2015, 101, 139-143.	0.6	6
182	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 591-597.	0.5	6
183	Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989028.	1.4	6
184	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	1.4	6
185	Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center. <i>Cancers</i> , 2021, 13, 2070.	1.7	6
186	FOLFOX4/XELOX in stage II-III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3501-3501.	0.8	6
187	An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab. <i>International Journal of Biological Markers</i> , 2015, 30, 73-80.	0.7	5
188	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. <i>Gastric Cancer</i> , 2017, 20, 428-437.	2.7	5
189	Hepatic and Extrahepatic Colorectal Metastases Have Discordant Responses to Systemic Therapy. Pathology Data from Patients Undergoing Simultaneous Resection of Multiple Tumor Sites. <i>Cancers</i> , 2021, 13, 464.	1.7	5
190	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. <i>Drugs and Aging</i> , 2021, 38, 579-591.	1.3	5
191	Off-label drug use in home palliative care: A non-evidence-based established practice.. <i>Journal of Clinical Oncology</i> , 2017, 35, 225-225.	0.8	5
192	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 5665.	1.7	5
193	Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 393-393.	0.8	5
194	Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.. <i>Journal of Clinical Oncology</i> , 2022, 40, 420-420.	0.8	5
195	Tumor-associated macrophages and risk of recurrence in stage III colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 307-312.	1.3	5
196	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4069-4069.	0.8	5
197	Serum Markers of Bone Metastases in Postmenopausal Breast Cancer Patients Treated with Formestane. <i>Tumor Biology</i> , 1997, 18, 197-205.	0.8	4
198	Biomarkers in Hepatocellular Carcinoma—Letter. <i>Clinical Cancer Research</i> , 2012, 18, 4861-4861.	3.2	4

#	ARTICLE	IF	CITATIONS
199	Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer. <i>Future Oncology</i> , 2019, 15, 2107-2112.	1.1	4
200	Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. <i>Health Science Reports</i> , 2020, 3, e147.	0.6	4
201	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021, 29, 3971-3980.	1.0	4
202	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	1.4	4
203	Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. <i>Clinical Drug Investigation</i> , 2021, 41, 795-808.	1.1	4
204	Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15607-e15607.	0.8	4
205	Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 198-199.	3.7	4
206	Sorafenib in Hepatitis C Virus–Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater!. <i>Journal of Clinical Oncology</i> , 2017, 35, 2213-2214.	0.8	3
207	Treatment-related toxicity predicts for improved outcome in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitor therapy. <i>Journal of Hepatology</i> , 2020, 73, S40-S41.	1.8	3
208	COVID-19 and liver cancer clinical trials: Not everything is lost. <i>Liver International</i> , 2020, 40, 1541-1544.	1.9	3
209	Metabolic Switch in Hepatocellular Carcinoma Patients Treated with Sorafenib: a Proof-of-Concept Trial. <i>Molecular Imaging and Biology</i> , 2020, 22, 1446-1454.	1.3	3
210	Pembrolizumab-Induced Vanishing Bile Duct Syndrome: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 906-908.	0.3	3
211	Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 197-197.	0.8	3
212	Caregiver stress: Clinical evaluation and intervention strategies for caregiver burden prevention.. <i>Journal of Clinical Oncology</i> , 2017, 35, 22-22.	0.8	3
213	Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS478-TPS478.	0.8	3
214	Antiangiogenic Drugs Currently Used for Colorectal Cancer: What Other Pathways Can We Target to Prolong Responses?. <i>Drug News and Perspectives</i> , 2007, 20, 307.	1.9	3
215	Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.. <i>Journal of Hepatology</i> , 2021, , .	1.8	3
216	Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 204.	1.1	3

#	ARTICLE	IF	CITATIONS
217	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 425-435.	1.9	3
218	Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4072-4072.	0.8	3
219	Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 570-574.	0.6	2
220	Shaping the landscape of immune oncology in hepatocellular carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 855-856.	5.1	2
221	Medical oncologists must get more involved in systemic treatment. <i>Annals of Oncology</i> , 2019, 30, 6-8.	0.6	2
222	Novel Therapies for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3049.	1.7	2
223	Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?. <i>Medical Oncology</i> , 2021, 38, 17.	1.2	2
224	Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). <i>Cancers</i> , 2021, 13, 1304.	1.7	2
225	Efficacy of oral chemotherapy with capecitabine and temozolomide (CapTem) in metastatic neuroendocrine tumors (NETs): A single-institution experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, 487-487.	0.8	2
226	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the "BRAF, BeCool" platform.. <i>Journal of Clinical Oncology</i> , 2018, 36, 639-639.	0.8	2
227	Another hospital admission through the emergency room? Looking for a fragility pattern in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 65-65.	0.8	2
228	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. <i>Annals of Translational Medicine</i> , 2020, 8, 1532-1532.	0.7	2
229	Intermediate-dose melphalan with stem-cell support in platinum-refractory ovarian cancer. <i>Bone Marrow Transplantation</i> , 2004, 33, 1261-1262.	1.3	1
230	Response to the Comments on Rimassa et al.: "Systemic Treatment Options in Hepatocellular Carcinoma" <i>Liver Cancer</i> , 2020, 9, 223-224.	4.2	1
231	Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 86-88.	0.7	1
232	Unravel hepatic artery infusion chemotherapy in patients with resected colorectal liver metastases. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 257-260.	0.7	1
233	Back to the basics: How the preclinical rationale shapes the immunotherapy landscape for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 5-6.	0.2	1
234	Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma. <i>Lancet Oncology</i> , The, 2021, 22, 896-898.	5.1	1

#	ARTICLE	IF	CITATIONS
235	A randomized phase II trial of second-line CAPTEM versus FOLFIRI in <i>MGMT</i> methylated, <i>RAS</i> mutated metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2019, 37, 3509-3509.	0.8	1
236	Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 341-341.	0.8	1
237	Current options and future directions of systemic therapy for advanced biliary tract cancer. Exploration of Targeted Anti-tumor Therapy, 2021, 2, .	0.5	1
238	Prognostic factors and disease course in patients enrolled onto clinical trials of second-line therapy for hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 406-406.	0.8	1
239	Drugs in Development for Hepatocellular Carcinoma. Gastroenterology and Hepatology, 2018, 14, 542-544.	0.2	1
240	Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2022, 40, 399-399.	0.8	1
241	High-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients. Annals of Oncology, 2006, 17, 719-720.	0.6	0
242	Reply to Y. Pointreau et al. Journal of Clinical Oncology, 2012, 30, 335-335.	0.8	0
243	Tivantinib for hepatocellular carcinoma. Expert Opinion on Orphan Drugs, 2015, 3, 343-351.	0.5	0
244	Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2021, 39, 4085-4085.	0.8	0
245	Are we ready for patient-reported outcomes in hepatocellular carcinoma?. The Lancet Gastroenterology and Hepatology, 2021, 6, 602-603.	3.7	0
246	Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).. Journal of Clinical Oncology, 2021, 39, 348-348.	0.8	0
247	Sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (HCC): Safety and efficacy in Child-Pugh (CP) class A and B patients.. Journal of Clinical Oncology, 2012, 30, 306-306.	0.8	0
248	CLINICAL AND ENDOCRINE EFFECTS OF MEGESTROL-ACETATE IN WOMEN WITH PRETREATED ADVANCED BREAST-CANCER. Oncology Reports, 1995, 2, 63-8.	1.2	0
249	ONC-2012-001: A single-arm phase II study of tivantinib (ARQ 197) plus cetuximab in EGFR inhibitor-resistant MET high patients (pts) with locally advanced or metastatic colorectal cancer (CRC) with wild-type KRAS.. Journal of Clinical Oncology, 2014, 32, TPS3661-TPS3661.	0.8	0
250	First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients (pts) with RAS wild-type, metastatic colorectal cancer (mCRC): The VALENTINO study.. Journal of Clinical Oncology, 2016, 34, TPS3634-TPS3634.	0.8	0
251	The behavior of colorectal liver metastases in the time frame between the end of preoperative chemotherapy and liver resection: A new selection criterion for technically resectable patients.. Journal of Clinical Oncology, 2017, 35, 665-665.	0.8	0
252	Abstract LB-232: Derazantinib (ARQ 087) pharmacodynamics: Alterations in FGF19/21/23 and phosphate in patients with cholangiocarcinoma. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
253	Nurses and health care assistants: Evaluation of attitude towards the care of patients who are terminally ill with cancer.. Journal of Clinical Oncology, 2018, 36, 158-158.	0.8	0
254	Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.. Journal of Clinical Oncology, 2019, 37, TPS4151-TPS4151.	0.8	0
255	Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer. , 2019, , .		0
256	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532.	0.7	0
257	The Immune Landscape in a Long-Term Survival Pancreatic Adenocarcinoma Patient Highly Responsive to a Multidisciplinary Approach With Chemo-Radio Treatments. Pancreas, 2021, 50, e76-e78.	0.5	0
258	Title is missing!. , 2020, 15, e0232371.		0
259	Title is missing!. , 2020, 15, e0232371.		0
260	Title is missing!. , 2020, 15, e0232371.		0
261	Title is missing!. , 2020, 15, e0232371.		0
262	Tumour burden score and immune-related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. Liver Cancer International, 0, , .	0.2	0